(NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, ...
Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. (NASDAQ: ...
Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National ...
Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes cited in the NCCN Clinical Practice Guidelines in Oncology and those recommended by the ...
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17 ...
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict ® are being featured at the 2017 San Antonio Breast ...
Hosted on MSN
Zydus Lifesciences signs deal with Myriad Genetics for cancer-risk assessment diagnostic tests
Zydus Lifesciences Ltd on Friday said it has signed an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India. Under the agreement, Zydus will ...
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results